ישראל - עברית - Ministry of Health

neopharm scientific ltd - a/california/7/2009 (h1n1)pdm09-like virus; a/hong kong/4801/2014 (h3n2) - like virus; b/brisbane/60/2008 - like virus - תרחיף להזרקה - b/brisbane/60/2008 - like virus 15 mcg / 0.5 ml; a/hong kong/4801/2014 (h3n2) - like virus 15 mcg / 0.5 ml; a/california/7/2009 (h1n1)pdm09-like virus 15 mcg / 0.5 ml - vaccinia immunoglobulin - vaccinia immunoglobulin - active immunisation against influenza in theelderly (65 years of age and over), especially for those with an infreased risk of associated complications (i.e. patients affected by underlying chronic diseases including diabetes, cardiovascular and respiratory diseases).

ישראל - עברית - Ministry of Health

neopharm scientific ltd - a/brisbane/02/2018(h1n1)pdm09-like virus; a/kansas/14/2017 (h3n2) like virus; b/colorado/06/2017- like virus (b/victoria/2/87 lineage); b/phuket/3073/2013 (b/yamagata lineage)-like virus - תרחיף להזרקה - b/phuket/3073/2013 (b/yamagata lineage)-like virus 15 mcg / 0.5 ml; b/colorado/06/2017- like virus (b/victoria/2/87 lineage) 15 mcg / 0.5 ml; a/kansas/14/2017 (h3n2) like virus 15 mcg / 0.5 ml; a/brisbane/02/2018(h1n1)pdm09-like virus 15 mcg / 0.5 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - prophylaxis of influenza.

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - rotavirus g1 reassortant; rotavirus g2 reassortant; rotavirus g3 reassortant; rotavirus g4 reassortant; rotavirus p1a[8] reassortant - suspension - rotavirus p1a[8] reassortant 2.3 x10 ^6 iu/dose; rotavirus g2 reassortant 2.8 x10 ^6 iu/dose; rotavirus g4 reassortant 2.0 x10^ 6 iu/dose; rotavirus g3 reassortant 2.2 x10 ^6 iu/dose; rotavirus g1 reassortant 2.2 x10 ^6 iu/dose - rota virus diarrhea vaccines - rotateq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes g1, g2, g3, and g4 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. the first dose of rorateq should be administered betwen 6 and 12 weeks of age.

ישראל - עברית - Ministry of Health

medici medical ltd, israel - a/michigan/45/2015 (h1n1)pdm09-like virus; a/singapore/infimh-16-0019/2016 (h3n2) - like virus; b/colorado/06/2017- like virus (b/victoria/2/87 lineage); b/phuket/3073/2013 - like virus (b/yamagata/16/88 lineage) - תרחיף להזרקה - b/phuket/3073/2013 - like virus (b/yamagata/16/88 lineage) 15 mcg/dose; a/michigan/45/2015 (h1n1)pdm09-like virus 15 mcg/dose; a/singapore/infimh-16-0019/2016 (h3n2) - like virus 15 mcg/dose; b/colorado/06/2017- like virus (b/victoria/2/87 lineage) 15 mcg/dose - influenza, inactivated, whole virus - influenza, inactivated, whole virus - for the prevention of influenza.

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - ספריי לאף - b/phuket/3073/2013 (b/yamagata lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/darwin/9/2021 (h3n2)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 7 ±0.5 log10 ffu^a / 0.2 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - flumist quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses ad type b viruses contained in the vaccine. flumist quadrivalent is approved for use in persons 2 through 49 years of age.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - live attenuated human rotavirus rix4414 strain - תרחיף - live attenuated human rotavirus rix4414 strain - rota virus, live attenuated - rota virus, live attenuated - rotarix is indicated for the active immunization of infants from the age of 6 weeks for prevention of gastro-enteritis due to rotavirus infection. in clinical trials, efficacy was demonstrated against gastro-enteritis due to rotavirus of types g1p[8], g2p[4], g3p[8], g4p[8] and g9p[8]. the use of rotarix should be based on official recommendations.

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd, israel - a/cambodia/e0826360/2020 (h3n2)-like strain; a/victoria/2570/2019 (h1n1)pdm09-like strain; b/washington/02/2019 (b/victoria lineage)-like virus - תרחיף להזרקה - b/washington/02/2019 (b/victoria lineage)-like virus 15 mcg/dose / 0.5 ml; a/cambodia/e0826360/2020 (h3n2)-like strain 15 mcg / 0.5 ml; a/victoria/2570/2019 (h1n1)pdm09-like strain 15 mcg / 0.5 ml - influenza, inactivated, split virus or surface antigen - influenza, inactivated, whole virus - influenza virus vaccine.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - hepatitis a virus antigen, inactivated - תרחיף להזרקה - hepatitis a virus antigen, inactivated 1440 e.l.u/ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - active immunisation against infections caused by hepatitis a virus.the vaccine is particularly indicated for those at increased risk of infection or transmission.

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - hepatitis a virus antigen, inactivated - תרחיף להזרקה - hepatitis a virus antigen, inactivated 25 units / 0.5 ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in children and adolescents 12 months of age and older .

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - hepatitis a virus antigen, inactivated - תרחיף להזרקה - hepatitis a virus antigen, inactivated 50 u/ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 2 years of age and older.